ClinicalTrials.gg
TerminatedNCT03702920APACHEUpdated Jun 4, 2026Results posted

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

A Phase 3 interventional study of SMT + PE-A 5% and Standard Medical Treatment in Acute-On-Chronic Liver Failure, sponsored by Instituto Grifols, S.A.. Terminated at 30 sites in 9 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Instituto Grifols, S.A. (part of Grifols) · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Due to corporate business reasons only (non-safety related decision)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
274
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

This is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to evaluate the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in acute-on-chronic liver failure (ACLF) subjects. The study will involve approximately 40 study centers in the United States, Canada, and Europe with expertise in the management of subjects with ACLF.

Subjects with ACLF at a high risk of hospital mortality will be enrolled. The study will consist of a Screening Period during which subjects will be randomized (1:1) to receive either standard medical treatment (SMT) + PE-A 5% (treatment group) or SMT only (control group), followed by a Treatment Period, and a Follow-up Period.

The Treatment Period for subjects in the SMT+ PE-A 5% treatment group will be between 7 and 17 days, depending on ACLF evolution.

The Treatment Period for subjects in the SMT control group will be a minimum of 7 days for all subjects and up to 17 days depending on the ACLF evolution. Subjects in this group will receive SMT according to the institution's standards.

The Follow-up Period for subjects in both groups will be 90 days.

Read the detailed description

Approximately 380 subjects with cirrhosis, ACLF, and high risk of hospital mortality (ACLF-1b, ACLF-2, or ACLF-3a) will be included in this study after obtaining written informed consent. In case of hepatic encephalopathy (HE), written informed consent will be obtained from a relative or a legally authorized representative if the subject is considered incompetent to consent.

Randomization of subjects will be stratified by region (European Union [EU] or North America [NA]) and the 3 ACLF grades (ACLF-1b, ACLF-2, or ACLF-3a). Within each stratum (ie, each unique combination of region and ACLF grade), subjects will be randomized in a 1:1 ratio into 2 treatment groups below:

  • SMT+PE-A 5% (treatment group)
  • SMT (control group)

SMT + PE-A 5% Treatment Group:

PE-A 5% will be performed using 5% albumin (Albutein® 5%) as the main replacement fluid administered intravenously. Fresh frozen plasma (FFP) will be given after each PE-A 5% session to prevent coagulopathy. SMT in addition to PE-A 5% will be administered according to institution standard practice.

The exact number of sessions will be determined by the pattern of response (achieving complete response or no improvement/deterioration of ACLF) to PE-A 5% therapy. IVIGs will be administered to prevent the development of hypogammaglobulinemia and infection.

SMT Control Group:

SMT will be administered according to institution standards practices.

Subjects in both the SMT+ PE-A 5% treatment group and the SMT control group will be followed for 90 days after randomization. During the entire study, the safety of both groups will be monitored by a Data Safety Monitoring Board.

02

Conditions studied

  • Acute-On-Chronic Liver Failure
03

In context

Acute-On-Chronic Liver Failure

167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.

This study's enrollment of 274 is above the median of 73 across 96 interventional studies indexed under Acute-On-Chronic Liver Failure.

Browse Acute-On-Chronic Liver Failure studies →

Lead sponsor

Instituto Grifols, S.A. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female cirrhotic subjects between 18 and 79 years of age.
  • Subjects with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalization (must be ACLF-1b, -2, or -3a within the Screening Period [a maximum of 10 days]).
  • Willing and able to provide written or have an authorized representative able to provide written informed consent on behalf of the subject in accordance with local law and institutional policy.
  • In case of HE, informed consent will be provided by a relative or a legally authorized representative if the subject is considered incompetent to consent.

Exclusion criteria

Exclusion Criteria:

  • Subjects without ACLF.
  • Subjects with ACLF-1a or ACLF-3b after the Screening Period.
  • Subjects fulfilling inclusion criteria that improve to no ACLF or to ACLF-1a or worsen to ACLF-3b during the Screening Period (between initial evaluation and time of randomization).
  • Subjects with ACLF for more than 10 days prior to randomization.
  • Subjects with acute or subacute liver failure without underlying cirrhosis.
  • Subjects with septic shock requiring use of norepinephrine (> 0.3 mcg/kg/min) or need for a second vasopressor (including terlipressin).
  • Subjects with active bacterial or fungal infection: who have received less than 24h of appropriate antibiotic treatment.
  • Subjects with severe respiratory failure with PaO2/FiO2 ≤200.
  • Subjects with active or recent bleeding (unless controlled for >48 hours).
  • Subjects with severe thrombocytopenia (≤20×10\^9/L) (based on local laboratory assessment).
  • Subjects with chronic renal failure and currently receiving hemodialysis.
  • Evidence of current locally advanced or . Subjects with hepatocellular carcinoma within the Milan criteria (1 nodule ≤5 cm or 3 nodules ≤3 cm), non-melanocytic skin cancer, and controlled breast or prostate cancer, can be included).
  • Subjects with severe chronic heart failure ( [NYHA] class III or IV).
  • Subjects with severe pulmonary disease (Global Obstructive Lung Disease [GOLD] stage III or IV).
  • Subjects with severe myopathy as defined clinically.
  • Subjects with a known infection with (HIV) or have clinical signs and symptoms consistent with current HIV infection.
  • Females who are pregnant, breastfeeding, or if of , unwilling to practice a highly effective method of .
  • Subjects with previous liver transplantation.
  • Subjects receiving anti- or anti-coagulant therapy (LMWH for DVT prophylaxis is allowed).
  • Participation in another clinical study within at least 30 days prior to screening.
  • Subjects with active drug addiction (exceptions: active alcoholism or marijuana).
  • Subjects with a do-not-resuscitate order.
  • In the opinion of the investigator, the subject may have compliance problems with the protocol and the procedures of the protocol.
  • Subjects with current infection of COVID-19, those who are less than 14 days post recovery or those who have clinical signs and symptoms consistent with COVID-19 infection.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
274 participants (actual)

Study arms

  • Experimental
    SMT + PE-A 5%

    PE-A 5% will be performed using 5% albumin (Albutein 5%) as the main replacement fluid administered intravenously. SMT in addition to PE-A 5% will be administered according to institution standards practice.

    Biological: SMT + PE-A 5%

  • Active comparator
    SMT Alone

    Standard medical treatment (SMT) will be administered according to institution standard practices.

    Other: Standard Medical Treatment

Interventions

  • BiologicalSMT + PE-A 5%

    Drug page: Albumins humanStudies of Albumins humanAlbumins human pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection. SMT in addition to PE-A 5% according to the institution's standard practice.

    Also known as: Albutein 5%

  • OtherStandard Medical Treatment

    Standard medical treatment according to the institution's standard practice

    Also known as: SMT

06

What researchers measure

Primary outcomes

  1. Time to Death Without a Prior Liver Transplant Through Day 90 After Randomization

    Time to 90-day overall survival was to be calculated as \[(date of death) - randomization date\] for those participants who died without having liver transplant on or prior to 90 days. Participants who did not die, or had a liver transplant before death were to have their time to event censored at the earlier of date of last contact, liver transplant date or cut-off date. The percentage of participants with events are presented. The percentage of participants was calculated as \[(participants with an event up to the analysis cut-off day) / (number of participants in the ITT group)\].

    Time frame: Up to Day 90

Secondary outcomes

  1. Time to Liver Transplant or Death Through Day 90 After Randomization

    Time to 90-day liver transplant free survival was calculated as \[the earlier of the date of liver transplantation or date of death - randomization date for those participants who died or had a liver transplant on or prior to 90 days\]. Participants who neither died nor had a liver transplant, were had their time to event censored at the earlier of date of last contact or cut-off date. The percentage of participants with events are presented. The percentage of participants was calculated as \[(participants with an event up to the analysis cut-off day) / (number of participants in the ITT group)\].

    Time frame: Day 1 to Day 90

  2. Time to Death Without a Prior Liver Transplant Through Day 28 After Randomization

    Time to 28-day overall survival was calculated as \[date of death - randomization date\] for those participants who died without having liver transplant on or prior to 28 days. Participants who did not die, or had a liver transplant before death were to have their time to event censored at the earlier of date of last contact, liver transplant date or cut-off date. The percentage of participants with events are presented. The percentage of participants was calculated as \[(participants with an event up to the analysis cut-off day) / (number of participants in the ITT group)\].

    Time frame: Day 1 to Day 28

07

Results

Posted Jun 4, 2026

Participant flow

A total of 274 participants took part in the study at 29 investigative sites across 8 countries in Europe and the United States from 17 June 2019 to 14 April 2025.

Participant flow — Overall Study
MilestoneSMT + PE-A 5%SMT Alone
Started135139
Completed3629
Not completed99110

Outcome measures

PrimaryTime to Death Without a Prior Liver Transplant Through Day 90 After Randomization

Time to 90-day overall survival was to be calculated as \[(date of death) - randomization date\] for those participants who died without having liver transplant on or prior to 90 days. Participants who did not die, or had a liver transplant before death were to have their time to event censored at the earlier of date of last contact, liver transplant date or cut-off date. The percentage of participants with events are presented. The percentage of participants was calculated as \[(participants with an event up to the analysis cut-off day) / (number of participants in the ITT group)\].

Time frame:
Up to Day 90
Reported as:
Count of participants · Participants
Time to Death Without a Prior Liver Transplant Through Day 90 After Randomization
ParticipantsSMT + PE-A 5%SMT Alone
Time to Death Without a Prior Liver Transplant Through Day 90 After Randomization5169
Statistical analysis
  • SMT + PE-A 5% vs SMT Alone · Cox Proportional- Hazards (PH) model · p = 0.021 · Hazard ratio (hr): 0.65 · 95% CI 0.45 to 0.94
SecondaryTime to Liver Transplant or Death Through Day 90 After Randomization

Time to 90-day liver transplant free survival was calculated as \[the earlier of the date of liver transplantation or date of death - randomization date for those participants who died or had a liver transplant on or prior to 90 days\]. Participants who neither died nor had a liver transplant, were had their time to event censored at the earlier of date of last contact or cut-off date. The percentage of participants with events are presented. The percentage of participants was calculated as \[(participants with an event up to the analysis cut-off day) / (number of participants in the ITT group)\].

Time frame:
Day 1 to Day 90
Reported as:
Count of participants · Participants
Time to Liver Transplant or Death Through Day 90 After Randomization
ParticipantsSMT + PE-A 5%SMT Alone
Time to Liver Transplant or Death Through Day 90 After Randomization8789
Statistical analysis
  • SMT + PE-A 5% vs SMT Alone · Cox Proportional-Hazard Model · p = 0.22 · Hazard ratio (hr): 0.83 · 95% CI 0.62 to 1.12
SecondaryTime to Death Without a Prior Liver Transplant Through Day 28 After Randomization

Time to 28-day overall survival was calculated as \[date of death - randomization date\] for those participants who died without having liver transplant on or prior to 28 days. Participants who did not die, or had a liver transplant before death were to have their time to event censored at the earlier of date of last contact, liver transplant date or cut-off date. The percentage of participants with events are presented. The percentage of participants was calculated as \[(participants with an event up to the analysis cut-off day) / (number of participants in the ITT group)\].

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Time to Death Without a Prior Liver Transplant Through Day 28 After Randomization
ParticipantsSMT + PE-A 5%SMT Alone
Time to Death Without a Prior Liver Transplant Through Day 28 After Randomization3951
Statistical analysis
  • SMT + PE-A 5% vs SMT Alone · Cox Proportional-Hazard Model · p = 0.06 · Hazard ratio (hr): 0.67 · 95% CI 0.44 to 1.01

Adverse events

Collected over Up to Day 90. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SMT + PE-A 5%51/135 (37.8%)37/128 (28.9%)79/128 (61.7%)
SMT Alone70/139 (50.4%)28/139 (20.1%)58/139 (41.7%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventSMT + PE-A 5%SMT Alone
Shock haemorrhagicVascular disorders3/1283/139
Transfusion-related acute lung injuryInjury, poisoning and procedural complications3/1281/139
Septic shockInfections and infestations2/1283/139
COVID-19Infections and infestations1/1283/139
PneumoniaInfections and infestations2/1282/139
Escherichia bacteraemiaInfections and infestations2/1280/139
Respiratory failureRespiratory, thoracic and mediastinal disorders2/1281/139
HypoxiaRespiratory, thoracic and mediastinal disorders2/1280/139
HypotensionVascular disorders2/1282/139
Staphylococcal bacteraemiaInfections and infestations1/1282/139
Most frequent other events
Showing 10 of 15
Most frequent other events
EventSMT + PE-A 5%SMT Alone
HypokalaemiaMetabolism and nutrition disorders18/12821/139
AnaemiaBlood and lymphatic system disorders18/12811/139
HypotensionVascular disorders14/12810/139
Urinary tract infectionInfections and infestations13/1286/139
Oedema peripheralGeneral disorders12/1285/139
DiarrhoeaGastrointestinal disorders11/1286/139
PneumoniaInfections and infestations3/12810/139
HypomagnesaemiaMetabolism and nutrition disorders8/1288/139
HyperglycaemiaMetabolism and nutrition disorders8/1286/139
HypophosphataemiaMetabolism and nutrition disorders8/1285/139

Baseline characteristics

Intent-to-treat (ITT) population included all participants who were randomized.

Age, Continuous
Age, Continuous(years)SMT + PE-A 5%SMT AloneTotal
Mean50.3 ± 10.9251.1 ± 11.4050.7 ± 11.15
Sex: Female, Male
Sex: Female, Male(Participants)SMT + PE-A 5%SMT AloneTotal
Female464288
Male8997186
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SMT + PE-A 5%SMT AloneTotal
American Indian or Alaska Native101
Asian044
Native Hawaiian or Other Pacific Islander000
Black or African American71219
White121118239
More than one race000
Unknown or Not Reported6511
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SMT + PE-A 5%SMT AloneTotal
Hispanic or Latino141731
Not Hispanic or Latino121122243
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)SMT + PE-A 5%SMT AloneTotal
United States494897
Austria7714
Belgium171734
France6511
Germany171431
Italy151631
Portugal325
Spain162137
United Kingdom5914
08

Study locations

30 sites
  • Southern California Research Center
    Coronado, California 92118, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Rutgers-New Jersey Medical School
    Newark, New Jersey 07101, United States
  • Mayo Clinic Rochester
    Rochester, New York 55905, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • McGuire VA Medical Center
    Richmond, Virginia 23249, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Aurora Health Care, Inc.
    Milwaukee, Wisconsin 53215, United States
  • Medical University of Vienna
    Vienna, A-1090, Austria
  • Université libre de Bruxelles
    Brussels, 1070, Belgium
  • UZ Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
  • Hôpital Beaujon
    Clichy, 92110, France
  • Centre Hépato-Biliaire - Hôpital Universitaire Paul Brousse
    Villejuif, 94804, France
  • Universitätsklinikum Frankfurt
    Frankfurt, 60590, Germany
  • Hannover Medical School
    Hanover, 30625, Germany
  • Universitaetsklinikum Leipzig
    Leipzig, 4103, Germany
  • Klinikum der Universitaet Muenchen
    München, 81377, Germany
  • Milano Hospital Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
    Milan, Milan 20122, Italy
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I
    Roma, Roma 161, Italy
  • ASST Grande Ospedale Metropolitano Niguarda
    Milan, 20162, Italy
  • Azienda Ospedaliera di Padova
    Padova, 35128, Italy
  • Centro Hospitalar do Porto
    Porto, Portugal
  • Hospital Universitario del Valle Hebron
    Barcelona, 08035, Spain
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Royal Free NHS Foundation Trust Hospital
    London, London NW3 2QG, United Kingdom
  • Nottingham University Hospital
    Nottingham, Nottingham NG72UH, United Kingdom
  • King's College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Apr 2025, 69 months.

Results were first posted in Jun 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2018
First posted
Oct 11, 2018
StartActual
Jun 17, 2019
Primary completionActual
Apr 14, 2025
CompletionActual
Apr 14, 2025
Results first posted
Jun 4, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03702920
Responsible party
Sponsor
First posted
Oct 11, 2018
Start date
Jun 17, 2019
Primary completion
Apr 14, 2025
Completion
Apr 14, 2025
Results posted
Jun 4, 2026
Last update
Jun 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumins human

Start the discussion